Laman UtamaANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Tutup sebelumnya
$0.00020
Permodalan pasaran
30.00 USD
Bilangan Purata
11.64K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
OTCMKTS
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | 2017info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 7.94J | -28.30% |
Pendapatan bersih | -26.87J | 51.60% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -3.80 | 70.53% |
EBITDA | -36.15J | 36.48% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | 2017info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 2.20J | -89.46% |
Jumlah aset | 3.67J | -84.35% |
Jumlah liabiliti | 9.17J | -13.70% |
Jumlah ekuiti | -5.50J | — |
Syer tertunggak | 23.40J | — |
Harga kepada buku | -0.00 | — |
Pulangan pada aset | -167.77% | — |
Pulangan pada modal | -619.42% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | 2017info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -26.87J | 51.60% |
Tunai daripada operasi | -36.90J | 24.57% |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | 18.25J | -22.58% |
Perubahan bersih dalam tunai | -18.65J | 28.58% |
Aliran tunai bebas | -23.15J | 18.17% |
Perihal
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Diasaskan
2004
Ibu pejabat
Tapak web
Pekerja
21
